ArticleOncogene2024

Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.

Marina G Ferrari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.